DSV A/S
DSV - Q1 2025 results and expected completion of Schenker acquisition analyst conference call
DSV - Q1 2025 results and expected completion of Schenker acquisition analyst conference call
We expect to complete the announced acquisition of Schenker and release the Q1 2025 interim results of DSV A/S on 30 April 2025. A conference call is scheduled for 11:30 am CEST.
At the conference call, Jens H. Lund, Group CEO, and Michael Ebbe, Group CFO, will present the Q1 2025 Interim Financial Report as well as further details and preliminary financial information related to the acquisition of Schenker. The presentation will be followed by a Q&A session.
Date: 30 April 2025
Time: 11:30 am CEST
To attend the webcast presentation, please go to Webcast presentation - DSV Interim Financial Report Q1 2025 or to https://investor.dsv.com/.
If you wish to ask questions during the conference call, please register through this link: Conference call Q&A - DSV Interim Financial Report Q1 2025. You will receive an email with dial-in telephone numbers.
We recommend participants to dial in 10 minutes prior to the scheduled start time.
Contacts
Investor Relations
Stig Frederiksen, tel. +45 43 20 36 38, stig.frederiksen@dsv.com
Alexander Plenborg, tel. +45 43 20 33 73, alexander.plenborg@dsv.com
Yours sincerely,
DSV A/S
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
EVS Broadcast Equipment18.4.2025 18:30:00 CEST | Press release
EVS Broadcast Equipment reports update of share buyback program
AMG Critical Materials N.V.18.4.2025 18:00:00 CEST | Press release
AMG Signs Exclusive Agreement with Grupo Lagoa
Syensqo SA18.4.2025 17:45:00 CEST | Press release
Syensqo - Acquisition of own shares
Ageas18.4.2025 17:40:00 CEST | Press release
Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV
Sanofi Winthrop Industrie18.4.2025 17:15:00 CEST | Press release
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom